{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T22:16:16Z","timestamp":1648592176239},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,3,20]],"date-time":"2018-03-20T00:00:00Z","timestamp":1521504000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s11096-018-0621-0","type":"journal-article","created":{"date-parts":[[2018,3,20]],"date-time":"2018-03-20T01:44:18Z","timestamp":1521510258000},"page":"608-616","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effectiveness and security of chronic hepatitis C treatment in coinfected patients in real-world"],"prefix":"10.1007","volume":"40","author":[{"given":"Mois\u00e9s","family":"Uriarte-Pinto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herminia","family":"Navarro-Aznarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"De La Llama-Celis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piedad","family":"Arazo-Garc\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Mar\u00eda","family":"Mart\u00ednez-Sapi\u00f1a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Reyes","family":"Abad-Sazatornil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,3,20]]},"reference":[{"key":"621_CR1","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1007\/s12072-015-9691-4","volume":"10","author":"M Mandorfer","year":"2016","unstructured":"Mandorfer M, Schwabl P, Steiner S, Reiberger T, Peck-Radosavljevic M. Advances in the management of HIV\/HCV coinfection. Hepatol Int. 2016;10:424\u201335.","journal-title":"Hepatol Int."},{"key":"621_CR2","unstructured":"WHO. Fact sheet hepatitis C 2015. World Health Organization. \n                    http:\/\/www.who.int\/mediacentre\/factsheets\/fs164\/es\/\n                    \n                  . Accessed 9 Feb 2017."},{"key":"621_CR3","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1136\/sextrans-2012-050566","volume":"88","author":"S Yaphe","year":"2012","unstructured":"Yaphe S, Bozinoff N, Kyle R, Shivkumar S, Pai NP, Klein M. Incidence of acute hepatitis C virus infection among men who have sex with men with and without HIV infection: a systematic review. Sex Transm Infect. 2012;88:558\u201364.","journal-title":"Sex Transm Infect."},{"key":"621_CR4","unstructured":"Crespo M, Von Wichmann MA. Manejo de las hepatitis virales en pacientes infectados por el VIH. Gu\u00eda de Pr\u00e1ctica Cl\u00ednica de GeSIDA. \n                    http:\/\/gesida-seimc.org\/category\/guias-clinicas\/otras-guias-vigentes\/page\/2\/\n                    \n                  . Accessed 9 Feb 2017."},{"key":"621_CR5","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1155\/2013\/781410","volume":"24","author":"M Hull","year":"2013","unstructured":"Hull M, Klein M, Shafran S, Tseng A, Gigu\u00e8re P, C\u00f4t\u00e9 P, et al. CIHR Canadian HIV trials network coinfection and concurrent diseases core: Canadian guidelines for management and treatment of HIV\/hepatitis C coinfection in adults. Can J Infect Dis Med Microbiol. 2013;24:217\u201338.","journal-title":"Can J Infect Dis Med Microbiol."},{"key":"621_CR6","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1086\/321909","volume":"33","author":"CS Graham","year":"2001","unstructured":"Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, Heeren T, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis. 2001;33:562\u20139.","journal-title":"Clin Infect Dis"},{"key":"621_CR7","first-page":"231","volume":"17","author":"E Poveda","year":"2015","unstructured":"Poveda E, Wyles D, Morano L, Pineda JA, Garc\u00eda F. News on HIV\u2013HCV Coinfection: update from the 2015 GEHEP conference. AIDS Rev. 2015;17:231\u20137.","journal-title":"AIDS Rev."},{"key":"621_CR8","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s11904-010-0071-3","volume":"8","author":"EA Operskalski","year":"2011","unstructured":"Operskalski EA, Kovacs A. HIV\/HCV co-infection: pathogenesis, clinical complications, treatment, and new therapeutic technologies. Curr HIV\/AIDS Rep. 2011;8:12\u201322.","journal-title":"Curr HIV\/AIDS Rep."},{"key":"621_CR9","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1002\/hep.23020","volume":"50","author":"J Berenguer","year":"2009","unstructured":"Berenguer J, \u00c1lvarez-Pellicer J, Mart\u00edn PM, L\u00f3pez-Aldeguer J, Von-Wichmann MA, Quereda C, et al. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology. 2009;50:407\u201313.","journal-title":"Hepatology"},{"key":"621_CR10","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1093\/cid\/civ396","volume":"61","author":"B Simmons","year":"2015","unstructured":"Simmons B, Saleem J, Heath K, Cooke GS, Hill A. Long-term treatment outcomes of patients infected with hepatitis C virus: a systematic review and meta-analysis of the survival benefit of achieving a sustained virological response. Clin Infect Dis. 2015;61:730\u201340.","journal-title":"Clin Infect Dis"},{"key":"621_CR11","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1093\/cid\/cis500","volume":"55","author":"J Berenguer","year":"2012","unstructured":"Berenguer J, Rodr\u00edguez E, Miralles P, Von Wichmann MA, L\u00f3pez-Aldeguer J, Mallolas J, et al. Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis. 2012;55:728\u201336.","journal-title":"Clin Infect Dis"},{"key":"621_CR12","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1517\/14656566.2015.1070828","volume":"16","author":"Z Mari\u00f1o","year":"2015","unstructured":"Mari\u00f1o Z, Lens S, Gambato M, Forns X. Advances in hepatitis C therapies. Expert Opin Pharmacother. 2015;16:1929\u201343.","journal-title":"Expert Opin Pharmacother"},{"key":"621_CR13","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.jhep.2013.11.003","volume":"60","author":"EASL Clinical Practice Guidelines","year":"2014","unstructured":"EASL Clinical Practice Guidelines. Management of hepatitis C virus infection. J Hepatol. 2014;60:392\u2013420.","journal-title":"J Hepatol"},{"key":"621_CR14","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1001\/jama.2014.7734","volume":"312","author":"MS Sulkowski","year":"2014","unstructured":"Sulkowski MS, Naggie S, Lalezari J, Fessel WJ, Mounzer K, Shuhart M, et al. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA. 2014;312:353\u201361.","journal-title":"JAMA"},{"key":"621_CR15","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa1501315","volume":"373","author":"S Naggie","year":"2015","unstructured":"Naggie S, Cooper C, Saag M, Workowski K, Ruane P, Towner WJ, et al. Ledipasvir and Sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015;373:705\u201313.","journal-title":"N Engl J Med"},{"key":"621_CR16","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1056\/NEJMoa1503153","volume":"373","author":"DL Wyles","year":"2015","unstructured":"Wyles DL, Ruane PJ, Sulkowski MS, Dieterich D, Luetkemeyer A, Morgan TR, et al. Daclatasvir plus Sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015;373:714\u201325.","journal-title":"N Engl J Med"},{"key":"621_CR17","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1001\/jama.2015.1328","volume":"313","author":"MS Sulkowski","year":"2015","unstructured":"Sulkowski MS, Eron JJ, Wyles D, Trinh R, Lalezari J, Wang C, et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA. 2015;313:1223\u201331.","journal-title":"JAMA"},{"key":"621_CR18","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1517\/17425255.2015.998997","volume":"11","author":"V Soriano","year":"2015","unstructured":"Soriano V, Labarga P, Barreiro P, Fernandez-Montero JV, de Mendoza C, Esposito I, et al. Drug interactions with new hepatitis C oral drugs. Expert Opin Drug Metab Toxicol. 2015;11:333\u201341.","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"621_CR19","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1038\/nrgastro.2013.106","volume":"10","author":"JJ Kiser","year":"2013","unstructured":"Kiser JJ, Burton JR, Everson GT. Drug\u2013drug interactions during antiviral therapy for chronic hepatitis C. Nat Rev Gastroenterol Hepatol. 2013;10:596\u2013606.","journal-title":"Nat Rev Gastroenterol Hepatol."},{"issue":"2","key":"621_CR20","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1517\/14656566.2016.1112790","volume":"17","author":"V Soriano","year":"2016","unstructured":"Soriano V, Labarga P, de Mendoza C, Fern\u00e1ndez-Montero JV, Esposito I, Ben\u00edtez-Guti\u00e9rrez L, et al. New hepatitis C therapies for special patient populations. Exp Opin Pharmacother. 2016;17(2):217\u201329.","journal-title":"Exp Opin Pharmacother"},{"key":"621_CR21","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1093\/cid\/civ438","volume":"61","author":"SD Shafran","year":"2015","unstructured":"Shafran SD. HIV coinfected have similar SVR rates as HCV monoinfected with DAAs: it\u2019s time to end segregation and integrate HIV patients into HCV trials. Clin Infect Dis. 2015;61:1127\u201334.","journal-title":"Clin Infect Dis"},{"key":"621_CR22","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1093\/cid\/civ1222","volume":"62","author":"S Saeed","year":"2016","unstructured":"Saeed S, Strumpf EC, Walmsley SL, Rollet-Kurhajec K, Pick N, Martel-Laferri\u00e8re V, et al. how generalizable are the results from trials of direct antiviral agents to people coinfected with HIV\/HCV in the real world? Clin Infect Dis. 2016;62:919\u201326.","journal-title":"Clin Infect Dis"},{"key":"621_CR23","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1093\/cid\/civ1215","volume":"62","author":"A Menard","year":"2016","unstructured":"Menard A, Colson P, Catherine D, Isabelle R, Christelle T, Meddeb L, et al. First real life evidence of new direct-acting antivirals (DAA) in co-infected HIV HCV patients: better than ever. Clin Infect Dis. 2016;62:947\u20139.","journal-title":"Clin Infect Dis"},{"key":"621_CR24","unstructured":"University of Liverpool. HEP drug interactions. \n                    http:\/\/www.hep-druginteractions.org\/\n                    \n                  . Accessed 10 Feb 2017."},{"key":"621_CR25","unstructured":"Lexicomp. \n                    http:\/\/online.lexi.com\/lco\/action\/interact\n                    \n                  . Accessed 10 Feb 2017."},{"key":"621_CR26","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios\u2014Ministerio de Sanidad Servicios Sociales e Igualdad. \n                    http:\/\/www.aemps.gob.es\/cima\/fichasTecnicas.do?metodo=buscar\n                    \n                  . Accessed 10 Feb 2017."},{"key":"621_CR27","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1016\/S0140-6736(00)03232-3","volume":"356","author":"G Greub","year":"2000","unstructured":"Greub G, Ledergerber B, Battegay M, Grob P, Perrin L, Furrer H, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet. 2000;356:1800\u20135.","journal-title":"Lancet"},{"key":"621_CR28","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1001\/jama.2014.7085","volume":"312","author":"A Kohli","year":"2014","unstructured":"Kohli A, Shaffer A, Sherman A, Kottilil S. Treatment of hepatitis C: a systematic review. JAMA. 2014;312:631\u201340.","journal-title":"JAMA"},{"key":"621_CR29","unstructured":"AEEH y SEIMC. Documento del III Consenso espa\u00f1ol sobre tratamiento de la hepatitis C. 2016. \n                    http:\/\/www.seimc.org\/grupodeestudio.php?Grupo=GEHEP&mn_Grupoid=14&mn_MP=512&mn_MS=513\n                    \n                  . Accessed 10 Feb 2017."},{"issue":"2","key":"621_CR30","doi-asserted-by":"publisher","first-page":"ofw059","DOI":"10.1093\/ofid\/ofw059","volume":"3","author":"J Berenguer","year":"2016","unstructured":"Berenguer J, Rivero A, Jarr\u00edn I, N\u00fa\u00f1ez MJ, Vivancos MJ, Crespo M, et al. Human immunodeficiency virus\/hepatitis C virus coinfection in Spain: prevalence and patient characteristics. Open Forum Infect Dis. 2016;3(2):ofw059. \n                    https:\/\/doi.org\/10.1093\/ofid\/ofw059\n                    \n                  .","journal-title":"Open Forum Infect Dis."},{"key":"621_CR31","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.4254\/wjh.v7.i12.1617","volume":"7","author":"LN Cavalcante","year":"2015","unstructured":"Cavalcante LN, Lyra AC. Predictive factors associated with hepatitis C antiviral therapy response. World J Hepatol. 2015;7:1617\u201331.","journal-title":"World J Hepatol."},{"key":"621_CR32","first-page":"47","volume":"9","author":"J Zhang","year":"2016","unstructured":"Zhang J, Nguyen D, Hu K-Q. Chronic hepatitis C virus infection: a review of current direct-acting antiviral treatment strategies. N Am J Med Sci. (Boston). 2016;9:47\u201354.","journal-title":"N Am J Med Sci. (Boston)"},{"key":"621_CR33","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1002\/hep.27726","volume":"61","author":"DR Nelson","year":"2015","unstructured":"Nelson DR, Cooper JN, Lalezari JP, Lawitz E, Pockros PJ, Gitlin N, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology. 2015;61:1127\u201335.","journal-title":"Hepatology"},{"key":"621_CR34","doi-asserted-by":"publisher","first-page":"2502","DOI":"10.1016\/S0140-6736(15)60159-3","volume":"385","author":"C H\u00e9zode","year":"2015","unstructured":"H\u00e9zode C, Asselah T, Reddy KR, Hassanein T, Berenguer M, Fleischer-Stepniewska K, et al. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Lancet. 2015;385:2502\u20139.","journal-title":"Lancet"},{"key":"621_CR35","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1089\/apc.2014.0247","volume":"29","author":"T-Y Chen","year":"2015","unstructured":"Chen T-Y, Jain MK. Treatment of hepatitis C in HIV-infected patients: moving towards an era of all oral regimens. AIDS Patient Care STDS. 2015;29:329\u201337.","journal-title":"AIDS Patient Care STDS."},{"key":"621_CR36","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1053\/j.gastro.2015.10.013","volume":"150","author":"MS Sulkowski","year":"2016","unstructured":"Sulkowski MS, Vargas HE, Di Bisceglie AM, Kuo A, Reddy KR, Lim JK, et al. Effectiveness of Simeprevir plus Sofosbuvir, with or without ribavirin, in real-world patients with HCV genotype 1 infection. Gastroenterology. 2016;150:419\u201329.","journal-title":"Gastroenterology"},{"key":"621_CR37","first-page":"SP198","volume":"22","author":"S Lakshmi","year":"2016","unstructured":"Lakshmi S, Alcaide M, Palacio AM, Shaikhomer M, Alexander AL, Gill-Wiehl G, et al. Improving HCV cure rates in HIV-coinfected patients\u2014a real-world perspective. Am J Manag Care. 2016;22:SP198\u2013204.","journal-title":"Am J Manag Care."},{"key":"621_CR38","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.jinf.2015.07.006","volume":"71","author":"JA Pineda","year":"2015","unstructured":"Pineda JA, N\u00fa\u00f1ez-Torres R, T\u00e9llez F, Mancebo M, Garc\u00eda F, Merchante N, et al. Hepatitis C virus reinfection after sustained virological response in HIV-infected patients with chronic hepatitis C. J Infect. 2015;71:571\u20137.","journal-title":"J Infect"},{"key":"621_CR39","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/j.jhep.2016.01.001","volume":"64","author":"H Midgard","year":"2016","unstructured":"Midgard H, Bj\u00f8ro B, M\u00e6land A, Konopski Z, Kileng H, Dam\u00e5s JK, et al. Hepatitis C reinfection after sustained virological response. J Hepatol. 2016;64:1020\u20136.","journal-title":"J Hepatol"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11096-018-0621-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-018-0621-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-018-0621-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,20]],"date-time":"2019-03-20T00:40:18Z","timestamp":1553042418000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11096-018-0621-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,20]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["621"],"URL":"https:\/\/doi.org\/10.1007\/s11096-018-0621-0","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,20]]},"assertion":[{"value":"28 August 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}